Log in

Start Your Membership Now

On January 24, 2019, the Office of the Inspector General (OIG) for the federal Department of Health and Human Services (HHS) issued an advisory opinion that will allow Otsuka Pharmaceutical Co., Ltd (Otsuka) to loan smartphones to people taking Abilify MyCite, a digital medicine device. Abilify MyCite is the tablet form of the antipsychotic aripiprazole manufactured with an embedded ingestible sensor developed by Proteus Digital Health. The sensor records that the medication was taken, and via a wearable patch communicates that information to a mobile application. The system consists of the pill, a patch, an app for the consumer, and . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: